Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Express Scripts
Medtronic
Colorcon
AstraZeneca

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206432

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 206432 describes NATEGLINIDE, which is a drug marketed by Alvogen, Cadila Pharms Ltd, Dr Reddys Labs Ltd, Par Pharm, Teva Pharms, Watson Labs, Wilshire Pharms Inc, and Zydus Pharms, and is included in eight NDAs. It is available from eleven suppliers. Additional details are available on the NATEGLINIDE profile page.

The generic ingredient in NATEGLINIDE is nateglinide. There are nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the nateglinide profile page.
Summary for 206432
Tradename:NATEGLINIDE
Applicant:Cadila Pharms Ltd
Ingredient:nateglinide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 206432
Mechanism of ActionPotassium Channel Antagonists
Suppliers and Packaging for NDA: 206432
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NATEGLINIDE nateglinide TABLET;ORAL 206432 ANDA Cadila Pharmaceuticals Limited 71209-030 71209-030-05 100 TABLET, COATED in 1 BOTTLE (71209-030-05)
NATEGLINIDE nateglinide TABLET;ORAL 206432 ANDA Cadila Pharmaceuticals Limited 71209-031 71209-031-05 100 TABLET, COATED in 1 BOTTLE (71209-031-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength60MG
Approval Date:Apr 19, 2019TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength120MG
Approval Date:Apr 19, 2019TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
Express Scripts
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.